BeOne chooses degradation over inhibition
The company sidelines CDK2 and pan-KRAS blockers, among other projects.
The month ahead: May’s upcoming events
ASCO looms, while FDA decisions are due on Enhertu and Inqovi.
SGO 2026 – GSK bucks the B7-H4 trend
The group impresses in ovarian and endometrial cancers.
BeOne looks to a degrader combo
Pivotal trials of sonrotoclax plus the group’s BTK degrader are set to start soon.
NK-cell engagers see another discontinuation
BeOne terminates a MUC1-targeting project.
ASCO-GI – Jazz sees a new Ziihera Herizon
But Tevimbra’s role looks shaky as adverse events loom.
BeOne starts another front-line sonrotoclax fight
The new phase 3 trial, in first-line CLL, is expected to begin in January 2026.
